1. Home
  2. RPD vs ACHV Comparison

RPD vs ACHV Comparison

Compare RPD & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rapid7 Inc.

RPD

Rapid7 Inc.

N/A

Current Price

$11.81

Market Cap

746.5M

Sector

Technology

ML Signal

N/A

Logo Achieve Life Sciences Inc.

ACHV

Achieve Life Sciences Inc.

N/A

Current Price

$7.99

Market Cap

618.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RPD
ACHV
Founded
2000
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
746.5M
618.0M
IPO Year
2015
2018

Fundamental Metrics

Financial Performance
Metric
RPD
ACHV
Price
$11.81
$7.99
Analyst Decision
Hold
Strong Buy
Analyst Count
23
3
Target Price
$15.05
$14.67
AVG Volume (30 Days)
2.3M
1.3M
Earning Date
05-05-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.11
N/A
Revenue
$685,083,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.54
N/A
P/E Ratio
$107.68
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.97
$2.62
52 Week High
$21.26
$8.61

Technical Indicators

Market Signals
Indicator
RPD
ACHV
Relative Strength Index (RSI) 53.30 69.43
Support Level $5.86 $4.09
Resistance Level $14.27 N/A
Average True Range (ATR) 0.96 0.38
MACD -0.06 0.13
Stochastic Oscillator 35.79 75.00

Price Performance

Historical Comparison
RPD
ACHV

About RPD Rapid7 Inc.

Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.

About ACHV Achieve Life Sciences Inc.

Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.

Share on Social Networks: